. Fixe-la-tumeur, A diff?rents temps, la souris sera anesth?si?e et passera sous le Nanospect

. Par-la-veine-caudale, Les images du Nanospect/CT et du Micro-PET sont acquises?1acquises?acquises?1 heure post-injection. Puis dans un second temps, nous injectons du 89 Zr-Df-Bz-NCS-Rituximab [100&l ; 1,2 MBq] par la veine caudale, Les images du Nanospect/CT et du Micro-PET sont acquises?24acquises?acquises?24, 48 et 72 heures post-injection afin dÕobserver la fixation de notre produit

. Hodgkin, On Some Morbid Appearances of the Absorbent Glands and Spleen, Journal of the Royal Society of Medicine, vol.17, issue.1, pp.68-114, 1832.
DOI : 10.1177/095952873201700106

R. W. Virchow and . Blut, Neue Notiz Gebiete Natur-und Heilkunde, pp.151-156, 1845.

C. Sternberg, ?ber eine eigenartige unter dem Bilde der Pseudoleuk?mie verlaufende Tuberkulose des lymphatischen Apparates. Zeitschrift Fur Heilkunde, pp.21-90, 1898.

D. Reed, On the pathological changes in Hodgkin's disease, with especial reference to its relation to tuberculosis, Johns Hopkins Hospital Reports, vol.10, pp.133-196, 1902.

N. Brill, G. Baehr, and N. Rosenthal, GENERALIZED GIANT LYMPH FOLLICLE HYPERPLASIA OF LYMPH NODES AND SPLEEN, Journal of the American Medical Association, vol.84, issue.9, pp.668-671, 1925.
DOI : 10.1001/jama.1925.02660350032008

J. Bruch, R. Duprez-paumier, and D. Sizaret, ??tude historique des lymphomes et de leurs classifications, Revue Francophone des Laboratoires, vol.2014, issue.458, pp.59-65, 2014.
DOI : 10.1016/S1773-035X(14)72316-0

K. Lennert, N. Mohri, and H. Stein, The Histopathology of Malignant Lymphoma, British Journal of Haematology, vol.71, issue.s1, pp.193-203, 1975.
DOI : 10.1016/S0140-6736(72)92215-5

R. Lukes and R. Collins, Immunologic characterization of human malignant lymphomas, Cancer, vol.58, issue.S8
DOI : 10.1002/1097-0142(197410)34:8+<1488::AID-CNCR2820340822>3.0.CO;2-C

N. Harris, E. Jaffe, and H. Stein, A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma study group, Current Diagnostic Pathology, vol.2, issue.1, pp.1361-1392, 1994.
DOI : 10.1016/S0968-6053(00)80051-4

S. Swerdlow, E. Campo, and N. Harris, WHO classification of tumours of haematopoietic and lymphoid tissues, 2008.

G. Salles, Les lymphomes malins, hodgkiniens et non hodgkiniens, 2011.

A. Monnereau, L. Remontet, and M. Maynadi?, Estimations nationale de lÕincidence des cancers en France entre, Septembre 2013, Partie 2 Ð h?mopathies malignes, pp.28-31, 1980.

M. Ochmann and . Th@bulletse, Lymphomes B inclassables avec des caract?ristiques interm?diaires entre lelymphome B diffus?grandesdiffus?diffus?grandes cellules et le lymphome de Burkitt : Evaluation r?trospective des caract?ristiques cliniques et impact de l'intensification th?rapeutique, 2013.

A. Smith, E. Roman, and D. Howell, The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research, British Journal of Haematology, vol.100, issue.5, pp.739-753, 2010.
DOI : 10.1111/j.1365-2141.2009.08010.x

S. Barrans, S. Crouch, and A. Smith, Is Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab, Journal of Clinical Oncology, vol.28, issue.20
DOI : 10.1200/JCO.2009.26.3947

A. Alizadeh, M. Eisen, and R. Davis, Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling, Nature, vol.303, issue.6769, pp.503-511, 2000.
DOI : 10.1038/35000501

A. Rosenwald, G. Wright, and W. Chan, The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma, New England Journal of Medicine, vol.346, issue.25, 2002.
DOI : 10.1056/NEJMoa012914

H. Tagawa, M. Suguro, and S. Tsuzuki, Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma, Blood, vol.106, issue.5, p.3052, 2005.
DOI : 10.1182/blood-2005-02-0542

G. Lenz, G. Wright, and S. Dave, Stromal Gene Signatures in Large-B-Cell Lymphomas, New England Journal of Medicine, vol.359, issue.22
DOI : 10.1056/NEJMoa0802885

C. Hans, D. Weisenburger, and T. Greiner, Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray, Blood, vol.103, issue.1, pp.275-282, 2004.
DOI : 10.1182/blood-2003-05-1545

R. Davis, K. Brown, and U. Siebenlist, Constitutive Nuclear Factor ??B Activity Is Required for Survival of Activated B Cell???like Diffuse Large B Cell Lymphoma Cells, The Journal of Experimental Medicine, vol.15, issue.12, pp.1861-1874, 2001.
DOI : 10.1016/S0960-894X(98)00029-8

U. Siebenlist, G. Franzoso, and K. Brown, Structure, regulation and function of NF-kB

M. Karin and Y. Ben-neriah, Phosphorylation Meets Ubiquitination: The Control of NF-??B Activity, Annual Review of Immunology, vol.18, issue.1, pp.621-663, 2000.
DOI : 10.1146/annurev.immunol.18.1.621

A. Baldwin, Control of oncogenesis and cancer therapy resistance by the transcription factor NF-??B, Journal of Clinical Investigation, vol.107, issue.3, pp.241-246, 2001.
DOI : 10.1172/JCI11991

J. Bodmer, P. Schneider, and J. Tschopp, The molecular architecture of the TNF superfamily, Trends in Biochemical Sciences, vol.27, issue.1, pp.19-26, 2002.
DOI : 10.1016/S0968-0004(01)01995-8

S. Kaur, G. Venktaraman, and M. Jain, Recent trends in antibody-based oncologic imaging, Cancer Letters, vol.315, issue.2, pp.97-111, 2012.
DOI : 10.1016/j.canlet.2011.10.017

C. Driol, Th?se de physique : Imagerie par rayonnement gamma diffus??hautediffus??diffus??haute sensibilit?, 2008.

A. Rahmim and H. Zaidi, PET versus SPECT: strengths, limitations and challenges, Nuclear Medicine Communications, vol.29, issue.3, pp.193-207, 2008.
DOI : 10.1097/MNM.0b013e3282f3a515

. Dans, M. Comet, and M. Vidal, Radiopharmaceutiques-Chimie des radiotraceurs et applications biologiques, pp.350-64, 1998.

H. Coenen, J. Mertens, and B. Maziere, Electrophilic substitution dans : Radioiodination reactions for pharmaeuticals, pp.45-62, 2006.

V. Ardisson, J. Mathieu, and C. Ghezzi, TEMP : les possibilit?s de marquagê lÕiode 123 ou au techn?tium. M?decine Nucl?aire -Imagerie fonctionnelle et m?tabolique, pp.29-33, 2005.

D. Wilbur, Radiohalogenation of proteins: An overview of radionuclides, labeling methods and reagents for conjugate labeling, Bioconjugate Chemistry, vol.3, issue.6, pp.433-470, 1992.
DOI : 10.1021/bc00018a001

M. Eder, S. Knackmuss, L. Gall, and F. , 68Ga-labelled recombinant antibody variants for immuno-PET imaging of solid tumours, European Journal of Nuclear Medicine and Molecular Imaging, vol.66, issue.Suppl 1, pp.1397-1407, 2010.
DOI : 10.1007/s00259-010-1392-6

K. Tamura, H. Kurihara, and K. Yonemori, 64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer, Journal of Nuclear Medicine, vol.54, issue.11, pp.1869-1875, 2013.
DOI : 10.2967/jnumed.112.118612

V. Behring, E. Kitasato, and S. , Ueber das zustandekommen der Diphterie-Immunit?t und der Tetanus-Immunit?t bei Thieren, Deutsch Medizinische Wochenschrift, vol.16, pp.1113-1114, 1890.

R. Porter, The formation of a specific inhibitor by hydrolysis of rabbit antiovalbumin, Biochemical Journal, vol.46, issue.4, pp.479-484, 1950.
DOI : 10.1042/bj0460479

A. Fagraeus, Antibody production in relation to the development of plasma cells, Acta Medica Scandinavica, vol.204, 1948.

H. Eisen and A. Keston, The immunologic reactivity of bovine serum albumin labeled with trace-amounts of radioactive iodine (I-131), The Journal of Immunology, vol.63, pp.71-80, 1950.

D. Pressman and L. Korngold, The in vivo localization of anti-Wagner-osteogenic-sarcoma antibodies, Cancer, vol.5, issue.3, pp.619-623, 1953.
DOI : 10.1002/1097-0142(195305)6:3<619::AID-CNCR2820060319>3.0.CO;2-Y

R. Sussman and S. Berson, Immunological specificity of human insulin : Application to immunoassay of insulin, The Journal of Clinical Investigation, vol.40, pp.2190-2198, 1961.

G. Kohler and C. Milstein, Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, vol.3, issue.5517, pp.495-497, 1975.
DOI : 10.1038/256495a0

J. Mach, J. Chatal, and J. Lumbroso, Tumor localization in patients by radiolabeled monoclonal antibodies against colon carcinoma, Cancer Research, vol.43, pp.5593-5600, 1983.

D. Goldenberg, F. Deland, and E. Kim, Use of Radio-Labeled Antibodies to Carcinoembryonic Antigen for the Detection and Localization of Diverse Cancers by External Photoscanning. The New England Jounal of Medicine, pp.1384-1388, 1978.

G. Kelloff, K. Krohn, and S. Larson, The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development, Clinical Cancer Research, vol.11, issue.22, pp.7967-7985, 2005.
DOI : 10.1158/1078-0432.CCR-05-1302

A. Herrington-symes, M. Farys, and H. Khalili, Antibody fragments: Prolonging circulation half-life special issue-antibody research, Advances in Bioscience and Biotechnology, vol.04, issue.05, 2013.
DOI : 10.4236/abb.2013.45090

URL : http://doi.org/10.4236/abb.2013.45090

Y. Fedor, Nouveau biomarqueur en temps r?el de cassures double-brin de lÕADN et g?notoxicit? de la Cytolethal Distending Toxin, Th?se Biologie Cellulaire, 2012.

I. Verel, G. Visser, and G. Van-dongen, The promise of immuno-PET in radioimmunotherapy, Journal of Nuclear Medicine, vol.46, pp.164-171, 2005.

P. B?rjesson, Y. Jauw, D. Bree, and R. , Radiation Dosimetry of 89Zr-Labeled Chimeric Monoclonal Antibody U36 as Used for Immuno-PET in Head and Neck Cancer Patients, Journal of Nuclear Medicine, vol.50, issue.11, pp.1828-1836, 2009.
DOI : 10.2967/jnumed.109.065862

P. B?rjesson, Y. Jauw, and R. Boellaard, Performance of Immuno-Positron Emission Tomography with Zirconium-89-Labeled Chimeric Monoclonal Antibody U36 in the Detection of Lymph Node Metastases in Head and Neck Cancer Patients, Clinical Cancer Research, vol.12, issue.7, pp.2133-2140, 2006.
DOI : 10.1158/1078-0432.CCR-05-2137

I. Verel, G. Visser, and R. Boellaard, 89 Zr immuno-PET: comprehensive procedures for the production of 89 Zr-labeled monoclonal antibodies, Journal of Nuclear Medicine, issue.8, pp.441271-1281, 2003.

S. Knowles, K. Zettlitz, and R. Tavar?, Quantitative ImmunoPET of Prostate Cancer Xenografts with 89Zr- and 124I-Labeled Anti-PSCA A11 Minibody, Journal of Nuclear Medicine, vol.55, issue.3, pp.452-459, 2014.
DOI : 10.2967/jnumed.113.120873

M. Vosjan, L. Perk, and S. Rispens, 89 Zr-Immuno-PET : Physical Properties, Production, Labeling and Applications of 89 Zr, 2012.

P. Frey, O. Townsend, and A. Jeavons, In vivo imaging of the human thyroid with a positron camera using 1-124, European Journal of Nuclear Medicine, vol.10, pp.472-476, 1985.

G. Fischer, U. Seibold, and R. Schirrmacher, 89Zr, a Radiometal Nuclide with High Potential for Molecular Imaging with PET: Chemistry, Applications and Remaining Challenges, Molecules, vol.18, issue.6, pp.6469-6490, 2013.
DOI : 10.3390/molecules18066469

. Cyclotron, Factsheet, iodine 124

J. Holland, Y. Sheh, and J. Lewis, Standardized methods for the production of high specific-activity zirconium-89, Nuclear Medicine and Biology, vol.36, issue.7, pp.729-739, 2009.
DOI : 10.1016/j.nucmedbio.2009.05.007

H. Oõbrien, Overview of radionuclides useful for radioimmunoimaging and radioimmunotherapy and current status of preparing radiolabelled antibodies

S. Knowles and A. Wu, Advances in ImmunoÐPositron Emission Tomography

E. Dijkers, O. Munnink, T. Kosterink, and J. , Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer, Clinical Pharmacology & Therapeutics, vol.87, issue.5, pp.586-592, 2010.
DOI : 10.1162/153535003322556877

E. Dijkers, J. Kosterink, and A. Rademaker, Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging, Journal of Nuclear Medicine, vol.50, issue.6, pp.974-981, 2009.
DOI : 10.2967/jnumed.108.060392

L. Perk, G. Visser, and M. Vosjan, 89 Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals 90 Y and 177 Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab, Journal of Nuclear Medicine, vol.46, pp.1898-1906, 2005.

T. Hehlgans and K. Pfeffer, The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games, Immunology, vol.163, issue.1, pp.1-20, 2005.
DOI : 10.1002/art.10968

J. Gross, J. Johnston, and S. Mudri, TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease, Nature, vol.404, issue.6781, pp.995-999, 2000.
DOI : 10.1038/35010115

S. Kim, S. Lee, and I. Choi, Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy, European Journal of Haematology, vol.91, issue.3
DOI : 10.1111/j.1600-0609.2008.01099.x

L. Willems and D. Bouscary, Signal Transduction, Correspondances en Onco-Hematologie, vol.32, pp.4-2011
DOI : 10.1002/0471141755.ph0200s56

J. Link, K. Krohn, and J. Eary, 89 Zr for antibody labeling and positron emission tomography, Journal of Labelled Compounds and Radiopharmaceuticals, vol.23, pp.1297-1298, 1986.

S. Ali and E. Shankland, Radiochemical synthesis of 89 Zr-porphyrin for positron label of monoclonal antibodies, Journal of Labelled Compounds and Radiopharmaceuticals, vol.30, p.326, 1991.

W. Meijs, J. Herscheid, and H. Haisma, Evaluation of desferal as a bifunctional chelating agent for labeling antibodies with Zr-89, International Journal of Radiation Applications and Instrumentation. Part A. Applied Radiation and Isotopes, vol.43, issue.12, pp.1443-1447, 1992.
DOI : 10.1016/0883-2889(92)90170-J

W. Meijs, H. Haisma, and R. Van-der-schors, A facile method for the labeling of proteins with zirconium isotopes, Nuclear Medicine and Biology, vol.23, issue.4, pp.439-448, 1996.
DOI : 10.1016/0969-8051(96)00020-0

W. Meijs, H. Haisma, and R. Klok, Zirconium-labeled monoclonal antibodies and their distribution in tumor-bearing nude mice, Journal of Nuclear Medicine, vol.38, pp.112-118, 1997.

L. Perk, M. Vosjan, and G. Visser, p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging, European Journal of Nuclear Medicine and Molecular Imaging, vol.37, issue.2, pp.250-259, 2010.
DOI : 10.1007/s00259-009-1263-1

M. Vosjan, L. Perk, and G. Visser, Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate pisothiocyanatobenzyldesferrioxamine, Nature Protocols, vol.5, p.4, 2010.

A. Natarajan, F. Habte, and S. Gambhir, Development of a Novel Long-Lived ImmunoPET Tracer for Monitoring Lymphoma Therap in a Humanized Transgenic Mouse Model

J. Mary, Quantification de prot?ines. www.labome.fr/method

J. Renart, J. Reiser, and G. Stark, Transfer of proteins from gels to diazobenzyloxymethylpaper and detection with antisera: a method for studying antibody specificity and antigen structure, Proceedings of the National Academy of Sciences, pp.3116-3120, 1979.

T. Lindmo, E. Boven, and F. Cuttitta, Determination of the immunoreactive function of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess, Journal of Immunological Methods, vol.72, issue.1, pp.77-89, 1984.
DOI : 10.1016/0022-1759(84)90435-6

K. Muylle, Immuno-PET imaging with 89Zr-rituximab in CD20+ B-cell lymphoma. Jules Bordet Cancer Institute, 2011.